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MEDICAL TREATMENT FOR CHRONIC MYELOID
LEUKAEMIA (CML):AVERAGE COST
EFFECTIVENESS RATIOS OF FIRST AND
SECOND LINE TREATMENT
Groot MT1, Ossenkoppele GJ2, Kramer MHH3,
van den Boom G4, Huijgens PC2, Uyl-de Groot CA1
1Erasmus University Rotterdam, Rotterdam, Netherlands; 2VU
Medical Centre, Amsterdam, Netherlands; 3Meander Medical
Centre, Amersfoort, Netherlands; 4Novartis Pharma B.V,
Arnhem, Netherlands
OBJECTIVE: To determine the average cost-effectiveness
ratios of interferon used ﬁrst line and imatinib used
second line in chronic phase CML. METHODS: A
general cost effectiveness analysis was performed. There-
fore, a model consisting of two phases is developed: an
induction phase of eight months, in which newly diag-
nosed patients are treated with two different doses of IFN
or patients refractory to IFN are treated with imatinib,
and a chronic treatment phase where patients are treated
according the result of the induction phase. Costs and
effects are modeled for a maximum of 25 years. Input 
for this model was derived from literature and expert
opinion. Costs are based on real cost prices and tariffs.
RESULTS: Compared to ﬁrst line IFN, treatment with
imatinib second line gives greater quality adjusted life
years (QALYs); 4.98 versus 6.67. Average costs of treat-
ment with 5MIU IFN are €76,969 and with 3MIU IFN
€53,257. For treatment with imatinib the total costs are
€140,765 per patient. Average cost-effectiveness ratios in
the 5MIU IFN group is €15,445 per QALY and €10,687
in the 3MIU IFN group. Using imatinib second line the
average cost-effectiveness ratio is €21,082 per QALY.
CONCLUSION: The addition of imatinib to the treat-
ment options in CML suggests that the costs of treatment
will rise but average survival and quality of life will also
considerably increase. The average costs per QALY are in
our view fully acceptable.
CANCER—Quality of Life/Preference Based
Outcomes
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CHILDHOOD,THEIR PARENTS AND THEIR
DOCTORS IN URUGUAY
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OBJECTIVES: The study assesses inter-rater agreement
of Health Utilities Index (HUI) measures reported for 103
survivors of cancers in childhood and 98 age-matched
controls (C) in Montevideo, Uruguay. METHODS: The
children completed face-to-face interviewer-administered
HUI health status questionnaires, Spanish language
version. Parents (P) and doctors (D) of the survivors, and
parents of 22 controls completed proxy-assessments.
Inter-rater agreement of HUI3 single-attribute and health-
related quality of life (HRQL) utility scores was assessed
between children and parents, children and doctors, and
parents and doctors using intra-class correlation coef-
ﬁcients (ICC). RESULTS: Agreement results vary by
attribute (vision, hearing, speech, ambulation, dexterity,
emotion, cognition, pain) but most are substantial (ICC
> 0.60). Due to lack of measurement variability, agree-
ment could not be assessed for HUI3 dexterity. As
hypothesized, agreement is generally substantial between
children and parents. ICC for overall HRQL and indi-
vidual attributes vision, hearing, speech, ambulation, cog-
nition, and pain, varying from 0.554 to 0.999 and all are
signiﬁcant at p < 0.0005. There is only slight agreement
(ICC < 0.20) for the highly subjective emotion attribute,
and that is consistent across all pairs of raters. Agreement
between children and doctors, and parents and doctors is
strongest for easily observed attributes, including vision,
hearing, speech and ambulation (p < 0.005), and weakest
for the less observable attributes (pain, cognition and
emotion). CONCLUSIONS: Results indicate that parents
are reliable proxies for assessing overall HRQL of their
children but parents and doctors may not have sufﬁcient
knowledge or insight into the pain, cognitive or emotional
burdens suffered by these young cancer survivors. These
results are consistent with those reported from an
English-language study of survivors of brain tumours 
in childhood in Hamilton, Canada. This consistency
between studies validates both the results and the
Spanish-language translation of the HUI.
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SPECIFIC CHOICES AND EXPENDITURES FOR
HERBAL MEDICINES BY CANCER PATIENTS
Arbuckle R, Leak JA, Roach P, Palmer JL, Hogervorst SL
The University of Texas M.D. Anderson Cancer Center,
Houston,TX, USA
OBJECTIVES: The use of alternative medicine is increas-
ing worldwide with total annual expenditures on herbal
medicine and/or supplements approaching 10 billion
dollars in the US alone. Cancer patients often feel uncom-
fortable discussing the use of herbals. This survey study
was designed to identify the types of herbals used, evalu-
ate the patients’ expectation of results of use, communi-
cation with the physician regarding use, out-of pocket
expenditure and possible correlations between these and
other demographic factors. METHODS: A survey con-
sisting of 17 questions was developed with a list of herbal
medications purchased by the patient. The instrument
was administered with the assistance of a nurse or phar-
macist to 450 patients in the Pre-op and Symptom and
Palliative Care Clinic (SCPC), 300 and 150 respectively.
The type and stage of cancer were retrieved from the
